you, for everyone. good Thank Mark, today. call and you Thank afternoon, joining our
are therapies neuroscience an if we options are and mental of by their and Vistagen, differentiated first-in-class a with disorders. widespread at neurological to whose deliver and the well-being intention whose satisfy adequate need psychiatric treatment Here FDA-approved any, pioneering health are adversely patients to disorders, where few, there for affected
candidates Each of neuroscience make care our and standards patients with improve potential lives. daily differences how clinical to new in stage to designed product establish the is their meaningful disorders their manage of
M&A we've the last a about in the $XX renaissance at in notably seen billion. valued few neuropsychiatry space by Within months, neuroscience, pharma marked
neuroscience programs stimulated We that with the are late-stage large encouraged novel differentiated safety with derived market in interest change lives. neuropsychiatry have to product potential candidates renewed profiles
disorders. clinical of in women's disorder, social neuroscience standard anxiety, potential multiple including diverse neuroactive depression, transform has We to and and large and market anchored our need produce the to treatment fasedienol and the is pherines, for areas of acute health anxiety need of the for led high other product with believe high care each innovation by differentiated novel across therapeutic profiles
of progress itruvone our PHXX. assets our of and pipeline, stage and discuss plans briefly three -- three fasedienol, of we'll neuroscience our Today, five for these clinical our in Pherin
the lives treatment of SAD, which lead of and aimed or with affects disorder, involves XX% population stage by about clinical is at adults costs opportunity their U.S. daily and the our noted, life. program affected very As anxiety high adult fasedienol transforming for social currently in paradigm the
daily their FDA-approved is them there safely SAD their still treatment stressors their While to address individuals life. the grow, continues upon prevalence in no to help option and acute when with SAD patient-tailored of rapidly are anxiety
development focused on program results last in and sheet, planned Phase III year reported positive a remaining that this key preparations we're our trial strong studies program. III balance with from year, for our the SAD, to fully initiate With PALISADE PALISADE-X all Phase advancing
remains adults by to with anxiety to in begin will That in in team conference of diligently initiated Phase half Since acute first of will be fasedienol anxiety social of of November, second on half disorder. III the be on focused our this which call our has That clinical our for to the been trial be the next last initiate track XXXX. followed in PALISADE-X the year. treatment preparations PALISADE-X, necessary
trials if Both public setting, with will challenge a primary as and efficacy in endpoint. support SUDS or effectiveness in speaking our the of for a Units We establish positive of reported submission PALISADE-X adults anxiety NDA a in PALISADE-X Phase of substantial III successful treatment may be Distressed patient outcomes from PALISADE-X PALISADE-X similar PALISADE-X will or to Scale results acute believe a of SAD. the fasedienol the Subjective with potential of PALISADE-X, trial. clinical involve either successful, on with together evidence
large has Phase or to anxiety back the of differentiated the up is without to been neuropsychiatry positive and that therapies never demonstrate market brain. Last the candidate that need results taken not concerns. sexual side into with that, liability forward clinic drug mission be year, knowledge, getting our abuse or to on our act of in directly PALISADE-X deliver the a III gain therapy soon, weight on something achieved, first-in-class driving in in to fast-acting a in effects, accomplished look does to We we systemically an continue risk a need study to neurons
for increasing transform ongoing. our without and market abuse this differentiated liability gain sexual Again, differentiated are our disorder, mission in trial for concerns. effects, Phase large weight fasedienol to in risk therapy monotherapy new MDD itruvone and we neuropsychiatry Phase itruvone the IIb our Preparations major or to unlock explore program or in potential Beyond depressive U.S. to a as planning significant potential the by a unfortunately the ways is SAD, various care MDD. deliver therapy of in III are standard side of continuing asset a to
PHXX rapid unreported also in previously is We in anchored onset hormone-free Its women's that we potential announced spray. the indications two in results from health see year. great last trials potential positive nasal our
to vasomotor or for or hot next, symptoms treatment of a the is management menopause. dysphoric for PMDD. flashes due First disorder pre-menstrual And
statistically studies. showed PHXX results significant in both
preparing PHXX studies development or due We nonclinical Phase II women's a moderate clinical health symptoms indications, are menopause. patients necessary for to of further IND to submit that treatment facilitate to conduct with to severe U.S. to vasomotor are of hot flashes including the
Cindy? now to I'll over highlights some the from to financial of our quarter 'XX. call Anderson third results CFO, turn Cindy fiscal our summarize of our the for the
